Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations Kuo, E., Santiago, V., Tanaka, K., Puram, V., Zhou, C., Tai, J. W., Mannis, G., Majeti, R., Zhang, T. Y. AMER SOC HEMATOLOGY. 2023

View details for DOI 10.1182/blood-2023-187644

View details for Web of Science ID 001159306707106